Verkäufer
PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
Verkäuferbewertung 4 von 5 Sternen
Heritage Bookseller
AbeBooks-Mitglied seit 1996
New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers FW-9780470281741
The science and applied approaches of enzyme inhibition in drug discovery and development
Offering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.
With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the "good" inhibitions―desirable pharmacological effects―and "bad" inhibitions―drug–drug interactions and toxicity. The book discusses:
The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment
The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions
The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway
Through this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.
Über die Autorin bzw. den Autor: Chuang Lu, PhD, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug–drug interaction, and in vitro–in vivo correlation.
Albert P. Li, PhD, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including Drug–Drug Interactions in Pharmaceutical Development, published by Wiley.
Titel: Enzyme Inhibition in Drug Discovery and ...
Verlag: Wiley
Erscheinungsdatum: 2010
Einband: HRD
Zustand: New
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. xiii 854 8 of lates Illus. Artikel-Nr. 8152767
Anzahl: 1 verfügbar
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Artikel-Nr. ABNR-245998
Anbieter: moluna, Greven, Deutschland
Zustand: New. Chuang Lu, PhD, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug-drug interaction, and in vitro-in vivo correlation.Albert P. Li, Ph. Artikel-Nr. 472613246
Anzahl: Mehr als 20 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Neuware - The science and applied approaches of enzyme inhibition in drug discovery and developmentOffering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, Enzyme Inhibition in Drug Discovery and Development examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.With chapters written by over fifty leading experts in their fields, Enzyme Inhibition in Drug Discovery and Development fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the 'good' inhibitions--desirable pharmacological effects--and 'bad' inhibitions--drug-drug interactions and toxicity. The book discusses:\* The drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment\* The manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug-drug interactions\* The inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathwayThrough this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK. Artikel-Nr. 9780470281741
Anzahl: 1 verfügbar
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
Hardcover. Zustand: Brand New. 1st edition. 854 pages. 10.00x6.25x1.75 inches. In Stock. Artikel-Nr. x-047028174X
Anzahl: 2 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. This book covers the science and approaches of enzyme inhibition applied in drug discovery and drug development, including both pharmacology and pharmacokinetic aspects of enzyme inhibition. Editor(s): Lu, Chuang; Li, Albert P. Num Pages: 868 pages, Illustrations. BIC Classification: MJ; MMG; PN. Category: (P) Professional & Vocational. Dimension: 244 x 167 x 44. Weight in Grams: 1324. . 2010. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland. Artikel-Nr. V9780470281741
Anzahl: 15 verfügbar